Trinity Life Sciences

Overview

Trinity Life Sciences is a technology-enabled life sciences commercialization firm operating at the intersection of strategy consulting, proprietary benchmarking data, and AI-powered SaaS analytics. Founded in 1996 and headquartered in Waltham, MA, Trinity structures its offerings around three commercial imperatives — optimize development, super-charge launch, and inflect your brand — spanning eight interconnected practice areas (Trinity About).

Core service lines include: corporate and commercial strategy (portfolio planning, asset valuation, forecasting); launch excellence via the proprietary Launch Accelerator platform; primary market research across HCP, patient, and payer stakeholders; evidence strategy and HEOR (health economic modeling, RWE, publication-grade research); value, access, and pricing (global pricing, payer contracting, HTA support — significantly expanded via the 2021 CBPartners acquisition adding 75+ dedicated experts); customer engagement and omnichannel analytics; and commercial data science (Trinity Services).

Trinity’s specialty within market access is its combination of deep launch analytics expertise — the firm claims involvement in ~70% of all new drug launches with up to 90% revenue prediction accuracy — with benchmarking intelligence that no pure consulting competitor can replicate (Trinity Homepage).

Competitive Positioning

Trinity’s primary differentiator is TGaS Advisors, its wholly owned benchmarking and advisory membership division. TGaS operates a subscription-based model with a majority of the top 50 pharma companies as members, generating proprietary, continuously updated commercial operations benchmarking data — an asset structurally unavailable to competitors. The membership model produces recurring revenue and creates a network moat: more members make the comparative intelligence more valuable (TGaS Benchmarking).

This creates a hybrid revenue model (project consulting + SaaS technology subscriptions via TrinityEDGE + membership benchmarking) that is more diversified and stickier than pure consulting, as Axios noted when covering the Bain minority investment. The Bain & Company strategic alliance (August 2022, with minority stake) further differentiates Trinity by providing upmarket C-suite transformation engagement access through Bain’s global reach across 60+ countries (Consulting.us).

Trinity was named one of only 10 Leaders (out of 30 evaluated) in Everest Group’s 2025 PEAK Matrix for Life Sciences AI & Analytics, positioning it alongside IQVIA and Accenture in AI credibility (Trinity Everest PEAK).

Recent Developments (2024-2026)

Leadership: New CEO Scott Evangelista appointed November 2025, succeeding Leslie Orne (24+ years at Trinity). Evangelista brings deep pharma operating experience — former President of Integrated Health Services at IQVIA, CEO of Cairn Therapeutics, Principal at Deloitte Life Sciences (Trinity Press Release).

Acquisitions: Acquired EVERSANA’s Asia-Pacific and Middle East advisory services (November 2025), adding offices in Singapore, Tokyo, Mumbai, Shanghai, Sydney, and Dubai — a major geographic expansion (Trinity APACME). Opened Mexico City office (July 2025).

Technology: Invested $100M+ in AI over five years; unveiled brand transformation emphasizing AI capabilities (October 2025). Launched Trinity Digital Affinity (HCP digital engagement, powered by DeepIntent, August 2025). Published AI model for early Type 1 diabetes detection at ADA 85th Scientific Sessions (July 2025). Named Everest Group PEAK Matrix Leader in Life Sciences AI & Analytics (Trinity Brand Transformation).

Recognition: Forbes Best Management Consulting Firms (2024, 2025); Inc. 5000 four consecutive years; Vault #1 health sciences consulting firm (2026).

Client Types

Trinity serves 350+ clients across large pharma (all top-50 via TGaS membership), mid-size biotech, emerging/pre-commercial biotech, and medtech/diagnostics companies. Therapeutic depth spans oncology (strongest franchise), rare/orphan disease, neurology, immunology, metabolic disease, respiratory, and ophthalmology. Named clients include GSK, Amgen, AstraZeneca, Eli Lilly, AbbVie, Pfizer, and Sarepta (Trinity Inc. 5000; FiercePharma).

Technology & Data

The TrinityEDGE platform is a modular suite including ForecastEDGE (enterprise forecasting), InsightsEDGE (role-specific AI advisors for brand leads, field reps, and MSLs), Launch Accelerator (cloud-based launch PMO), and RealWorldEDGE (RWE analytics) (TrinityEDGE). Trinity maintains an extensive data alliance ecosystem spanning IQVIA, Komodo Health, HealthVerity, Definitive Healthcare, Flatiron, ConcertAI, Optum, IntegriChain, MMIT, and Ontada (McKesson) (Trinity Alliances).

Financial Context

Ownership: Kohlberg & Company acquired Trinity in November 2021 at ~$1.4B enterprise value (17-23x EBITDA), providing exit for Parthenon Capital Partners. Bain & Company took a minority stake in August 2022 (Axios).

Scale: ~1,300 employees, 14 offices across 5 continents. Revenue is not disclosed but analyst inference based on headcount, valuation multiples, and growth trajectory suggests $250-400M+. Headcount grew from ~250 (2018) to 1,300 (2025) — roughly 5x in seven years.

Kohlberg ecosystem: Kohlberg has built a deliberate non-competing pharma services platform: Trinity (commercialization), PCI Pharma Services (CDMO), and Worldwide Clinical Trials (CRO). Operating partner Matt Jennings chairs boards at both Trinity and Worldwide, describing it as “building a vital piece of our pharma services ‘ecosystem’” (BioXconomy).

Note on ConnectiveRx: Research indicates ConnectiveRx is owned by Genstar Capital, not Kohlberg. They are not portfolio siblings (Genstar Capital).

Analyst Observations

Trinity’s combination of TGaS benchmarking data, $100M+ AI investment, and the Bain alliance creates a defensible competitive position that pure consulting firms struggle to replicate. The hybrid revenue model (consulting + SaaS + membership) is structurally more attractive than project-only firms for PE exit valuation purposes. Key risks include CEO transition (Evangelista is Trinity’s third CEO in a short period), APACME integration complexity, and Kohlberg exit timing — typical 4-7 year hold suggests a potential exit in 2025-2028, with the brand transformation, Bain relationship, and Everest Group recognition looking like pre-exit value creation steps. Trinity is a strong acquisition target for larger platforms seeking a pharma commercialization data/analytics moat. IRA pricing tailwinds are a direct growth catalyst for their HEOR and market access practices.

Related concepts: Gross-to-Net, Biosimilars & Pharma Services, Specialty Drug Commercialization

Sources

• Trinity Life Sciences website
• Trinity Services
• TGaS Benchmarking
• TrinityEDGE
• Trinity Alliances
• Axios — Bain minority investment
• Consulting.us — Bain stake
• Everest Group PEAK Matrix 2025
• Trinity APACME acquisition
• Trinity Brand Transformation
• FiercePharma
• BioXconomy — Kohlberg ecosystem
• Wave 3 Batch D research